The EBAG9 Knockout HGC-27 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the HGC-27 gastric carcinoma cell line. This product features targeted disruption of the EBAG9 (estrogen receptor-binding fragment-associated antigen 9) gene, providing a versatile model for loss-of-function studies. The polyclonal nature ensures a heterogeneous pool of knockout variants, reflecting population-level genetic diversity. Cells are delivered as a living polyclonal pool, optimized for immediate experimental use in cancer immunology and signaling research.
HGC-27 is a human gastric carcinoma epithelial cell line originally established from a lymph node metastasis of a gastric adenocarcinoma. As a metastatic derivative, HGC-27 retains key characteristics of advanced gastric cancer, including invasive properties and responsiveness to microenvironmental cues. This cell line serves as a robust in vitro platform for investigating molecular mechanisms underlying tumor progression and immune interactions within the gastric cancer milieu.
EBAG9 encodes an estrogen-responsive protein, also known as RCAS1, that functions as a ligand for an as-yet-unidentified lymphocyte receptor. Activation of this pathway induces caspase-3- and caspase-9-dependent apoptosis in tumor-infiltrating lymphocytes, thereby promoting immune evasion. EBAG9 expression is upregulated by estrogen receptor alpha (ER??) and estradiol, linking hormonal signaling to immune escape. Putative interactions with Bcl-2 family proteins suggest additional regulatory nodes within the extrinsic apoptotic cascade. Thus, EBAG9 operates at the intersection of endocrine signaling and immune checkpoint-like mechanisms.
In HGC-27 cells, EBAG9 overexpression mirrors clinical observations in gastric cancer, where it contributes to lymphocyte apoptosis and reduced anti-tumor immunity. Disruption of EBAG9 in this context enables researchers to dissect how estrogen-driven immune suppression facilitates tumor growth. The knockout model is particularly valuable for assessing changes in susceptibility to T-cell- or NK-cell-mediated killing, and for exploring the re-engagement of cytotoxic immune responses following loss of this immunomodulatory factor.
This polyclonal knockout population supports a wide range of experimental applications, including co-culture apoptosis assays with peripheral blood lymphocytes, RT-qPCR and western blotting for target engagement validation, flow cytometry-based immune cell viability assessments, and tumor xenograft studies to evaluate immune infiltration. It is an ideal tool for therapeutic target validation, screening of immune-modulating compounds, and mechanistic investigations into estrogen-driven immune evasion. For more information or custom requests, please contact Ascent Research.
